Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesConivaptan: promise of treatment in heart failure
Expert Opinion in Pharmacotherapy, 08/14/09
Hoque MZ et al. – Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V1a and V2 receptors. In this article authors review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.
Related Articles
Heart failure may worsen with statins
CNN Health, 11/06/09
Relevance Score: 71%
Death and Dying in Heart Failure With Normal Ejection Fraction
The American Journal of Cardiology, 10/27/09
Relevance Score: 70%
Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure - Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes
Cardiology, 10/22/09
Relevance Score: 70%
Fatigue in elderly with chronic heart failure: an under-recognized symptom
Aging Health, 10/14/09
Relevance Score: 70%
Central Aortic Stiffness is Increased in Patients With Heart Failure and Preserved Ejection Fraction
Journal of Cardiac Failure, 10/05/09
Relevance Score: 70%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Review: aspirin reduces vascular events but increases bleeding in primary and secondary prevention
Evidence-Based Medicine, 12/07/09
In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status
Evidence-Based Medicine, 12/07/09
Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease
Clinical Therapeutics, 12/07/09
Sponsor
Article Search
Sponsor